Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development…
- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting,…
Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:…
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to…
Study to assess new camptothecin-peptide conjugates for the treatment of sortilin-positive colorectal cancers Separate data to highlight activity of sudocetaxel…
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a…
Company generated approximately $2.8M of non-dilutive funding to extend cash runwayWESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech…
Bernard Coulie and Kevin Marks bring significant corporate, drug development, and compliance experience to the CMTA BoardThe CMTA Board and…
Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc.…
Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows…